LEIDEN, the Netherlands, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to
changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today
announced that the company will give a presentation at the Chardan Genetic Medicine Conference to be held at Westin Grand Central,
New York, NY.
Presentation format: Fireside chat
Presenter: Gerard Platenburg, chief innovation officer of ProQR
Presentation: Tuesday, October 9, 2018 at 8:00 am ET
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of
severe genetic rare diseases such as Leber’s congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis. Based
on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar
expressions. Such statements include those relating to our participation at the Chardan Genetic Medicine Conference.
Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of
the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking
statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the
Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks,
uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new information becomes available in the future, except as required
by law.
ProQR Therapeutics N.V.
Investor Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com
Media Contact:
Sara Zelkovic
LifeSci Public Relations
T: +1 646 876 4933
Sara@lifescipublicrelations.com
